Menu Search
Equities

Kangmei Pharmaceutical Co Ltd

600518:SHH

Kangmei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.66
  • Today's Change-0.17 / -6.01%
  • Shares traded2.34bn
  • 1 Year change+42.25%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Kangmei Pharmaceutical Co Ltd grew revenues 16.60% from 4.18bn to 4.87bn while net income improved from a loss of 2.69bn to a gain of 102.52m.
Gross margin20.63%
Net profit margin4.95%
Operating margin3.55%
Return on assets1.80%
Return on equity3.69%
Return on investment2.77%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Kangmei Pharmaceutical Co Ltd fell by 476.01m. Cash Flow from Investing was negative at 37.64m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 317.52m for operations while cash used for financing totalled 120.85m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.5079
Tangible book value per share0.4667
More ▼

Balance sheet in CNYView more

Kangmei Pharmaceutical Co Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 3.46%.
Current ratio1.43
Quick ratio0.8398
Total debt/total equity0.036
Total debt/total capital0.0346
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.